Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.
- DOI
- 10.1182/bloodadvances.2024013474
- Published
- 2025 Jan 14
- Container
- Blood advances
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2024013474,
title = {Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.},
author = {Shanafelt TD and Wang XV and Hanson CA and Paietta E and O'Brien S and Barrientos J and Jelinek DF and Braggio E and Leis JF and Zhang CC and Barr PM and Cashen AF and Mato AR and Singh AK and Mullane MP and Little RF and Erba H and Stone RM and Litzow M and Tallman M and Kay NE},
year = {2025},
journal = {Blood advances},
doi = {10.1182/bloodadvances.2024013474},
url = {https://doi.org/10.1182/bloodadvances.2024013474}
}RIS
TY - JOUR TI - Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912. AU - Shanafelt TD AU - Wang XV AU - Hanson CA AU - Paietta E AU - O'Brien S AU - Barrientos J AU - Jelinek DF AU - Braggio E AU - Leis JF AU - Zhang CC AU - Barr PM AU - Cashen AF AU - Mato AR AU - Singh AK AU - Mullane MP AU - Little RF AU - Erba H AU - Stone RM AU - Litzow M AU - Tallman M AU - Kay NE PY - 2025 JO - Blood advances DO - 10.1182/bloodadvances.2024013474 UR - https://doi.org/10.1182/bloodadvances.2024013474 ER -
APA
TD, S., XV, W., CA, H., E, P., S, O., J, B., DF, J., E, B., JF, L., CC, Z., PM, B., AF, C., AR, M., AK, S., MP, M., RF, L., H, E., RM, S., M, L., M, T., & NE, K. (2025). Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.. Blood advances. https://doi.org/10.1182/bloodadvances.2024013474
Source records
- pubmed · retrieved 2026-09-27T01:34:53.787Z